Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

ERR2278850

—

2082f890-3687-5400-b19a-f80c2e5fd3fe

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • CHOLESTEROL_HOMEOSTASIS+0.410
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
  • ANGIOGENESIS+0.360
  • TNFA_SIGNALING_VIA_NFKB+0.330
  • APICAL_SURFACE+0.290
  • TGF_BETA_SIGNALING+0.270
  • HYPOXIA+0.260
  • APICAL_JUNCTION+0.250
  • COAGULATION+0.250
  • GLYCOLYSIS+0.180

Top 10 suppressed

  • MYC_TARGETS_V2-0.310
  • ALLOGRAFT_REJECTION-0.290
  • E2F_TARGETS-0.240
  • ADIPOGENESIS-0.200
  • INTERFERON_GAMMA_RESPONSE-0.190
  • OXIDATIVE_PHOSPHORYLATION-0.190
  • G2M_CHECKPOINT-0.180
  • INTERFERON_ALPHA_RESPONSE-0.180
  • MYC_TARGETS_V1-0.180
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.180

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG119
mng-umap@100
——0.805
2TCGA-A1-A0SM-01A-11R-A084-07
breast-umap@18
—C0.801
3MNG115
mng-umap@100
——0.800
4TCGA-CQ-7069-01A-11R-2403-07
head-neck@1
——0.783
5TCGA-DQ-5624-01A-01R-1873-07
head-neck@1
——0.763
6TCGA-BA-6868-01B-12R-1915-07
head-neck@1
——0.760
76b548699-9440-4acc-86b6-faeb367454a2
colon-landscapes@1
——0.755
820030016.LumA
breast-umap@18
—B0.755
920030015.LumB
breast-umap@18
—A0.753
10TCGA-E2-A153-01A-12R-A12D-07
breast-umap@18
—A0.753

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
CHOLESTEROL_HOMEOSTASIS0.410Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.370Inavolisib— uncovered
ANGIOGENESIS0.360Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.330Inavolisib— uncovered
APICAL_SURFACE0.290Temsirolimus— uncovered
TGF_BETA_SIGNALING0.270Inavolisib— uncovered
HYPOXIA0.260Idelalisib— uncovered
APICAL_JUNCTION0.250Inavolisib— uncovered
COAGULATION0.250Binimetinib— uncovered
GLYCOLYSIS0.180Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.170Inavolisib— uncovered
APOPTOSIS0.160Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.160Idelalisib— uncovered
P53_PATHWAY0.160Idelalisib— uncovered
UV_RESPONSE_UP0.160Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.140Idelalisib— uncovered
PROTEIN_SECRETION0.140Remibrutinib— uncovered
ANDROGEN_RESPONSE0.130Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.120Inavolisib— uncovered
PANCREAS_BETA_CELLS0.120Cobimetinib— uncovered